AstraZeneca splashes out up to $320M on T-cell receptor therapy company
Neogene Therapeutics, Inc., a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of…
November 30, 2022 - 3 minutes
AstraZeneca
Licensing agreement signed for C4XD between C4X Discovery and AstraZeneca
C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca. It is worth…
November 28, 2022 - 3 minutes
AstraZeneca and Daiichi Sankyo’s Enhertu recommended for approval
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) for patients…
November 18, 2022 - 3 minutes
In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus
AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the European Union (EU) for the…
November 14, 2022 - 9 minutes
Sanofi and AstraZeneca drug, Beyfortus, for RSV in babies and children approved
A drug being developed jointly by Sanofi and AstraZeneca for the prevention of respiratory syncytial…
November 4, 2022 - 2 minutes
Illumina and AstraZeneca look to drug target discovery with ‘pivotal research collaboration’
Illumina Inc. has announced a strategic research collaboration with AstraZeneca to accelerate drug target discovery…
October 11, 2022 - 2 minutes
ASPIRE set up to collaborate on amyloidosis
A new group of biotech and pharma companies has been assembled by the Amyloidosis Research…
October 4, 2022 - 3 minutes
Alexion, AstraZeneca Rare Disease to acquire genomic medicine company LogicBio Therapeutics
LogicBio Therapeutics, Inc. has entered into a definitive agreement under which Alexion, AstraZeneca Rare Disease…
October 3, 2022 - 3 minutes
CHMP recommends approval of Beyfortus for prevention of RSV disease in infants
Beyfortus, which is being developed jointly by Sanofi and AstraZeneca, is a step closer to…
September 16, 2022 - 4 minutes
Ionis presents positive study results at International Symposium on amyloidosis
Ionis Pharmaceuticals, Inc. has presented positive results from a planned 35-week interim analysis of the…
September 7, 2022 - 4 minutes
Acquisition of TeneoTwo and its clinical-stage T-cell engager completed
AstraZeneca has said today (August 11) that it has completed its purchase of TeneoTwo including…
August 11, 2022 - 2 minutes
Lung cancer trial patients responding well to combination treatment offered by HUTCHMED and AstraZeneca
A medication used to treat non-small cell lung carcinomas (NSCLC) with specific mutations has demonstrated…
August 8, 2022 - 3 minutes
